Overview

Early Treatment of Cytokine Storm Syndrome in Covid-19

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.

Phase:

Phase 3

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Interleukin 1 Receptor Antagonist Protein